Neumeister Veronique M, Juhl Hartmut
Indivumed, GmbH, Falkenried 88, D-20251 Hamburg, Germany.
Curr Pathobiol Rep. 2018;6(4):265-274. doi: 10.1007/s40139-018-0179-5. Epub 2018 Sep 6.
Precision medicine promises patient tailored, individualized diagnosis and treatment of diseases and relies on clinical specimen integrity and accuracy of companion diagnostic testing. Therefore, pre-analytics, which are defined as the collection, processing, and storage of clinical specimens, are critically important to enable optimal diagnostics, molecular profiling, and clinical decision-making around harvested specimens. This review article discusses the impact of tumor pre-analytics on molecular pathology focusing on biospecimen protein expression and analysis.
Due to busy clinical schedules and workflows that have been established for many years and to lack of standardization and limited assessment tools to quantify variability in pre-analytical processing, the effects of pre-analytics on biospecimen integrity are often overlooked. Several studies have recently emphasized an emerging crisis in science and reproducibility of results.
Biomarker instability due to pre-analytical variables affects comprehensive analysis and molecular phenotyping of patients' tissue. This problematic emphasizes the critical need for standardized protocols and technologies to be applied in the clinical and research setting.
精准医学致力于为患者提供量身定制的个性化疾病诊断和治疗,其依赖于临床标本的完整性以及伴随诊断检测的准确性。因此,定义为临床标本采集、处理和储存的分析前阶段对于实现围绕采集标本的最佳诊断、分子分析和临床决策至关重要。本文综述讨论了肿瘤分析前阶段对分子病理学的影响,重点关注生物标本的蛋白质表达和分析。
由于繁忙的临床日程安排、多年来已确立的工作流程,以及缺乏标准化和有限的评估工具来量化分析前处理中的变异性,分析前阶段对生物标本完整性的影响常常被忽视。最近的几项研究强调了科学领域出现的危机以及结果的可重复性问题。
分析前变量导致的生物标志物不稳定会影响对患者组织的全面分析和分子表型分析。这一问题凸显了在临床和研究环境中应用标准化方案和技术的迫切需求。